Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Sonal, Paul"'
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Autor:
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato
Publikováno v:
Hepatology Communications, Vol 6, Iss 7, Pp 1776-1785 (2022)
Abstract The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. Th
Externí odkaz:
https://doaj.org/article/e44c4fda0f48434e9cdc4675c1f8ec5f
Autor:
Petros Fessas, Muntaha Naeem, Matthias Pinter, Thomas U. Marron, David Szafron, Lorenz Balcar, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Elad Sharon, Alessio Cortellini, David J. Pinato
Publikováno v:
Liver Cancer, Vol 10, Iss 6, Pp 583-592 (2021)
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indicatio
Externí odkaz:
https://doaj.org/article/5b2616ec247c4eb78946d132559d4210
Autor:
Tomi Jun, Umut Ozbek, Sirish Dharmapuri, Camille Hardy-Abeloos, Huili Zhu, Jung-Yi Lin, Nicola Personeni, Tiziana Pressiani, Naoshi Nishida, Pei-Chang Lee, Chieh-Ju Lee, Hannah Hildebrand, Neil Nimkar, Sonal Paul, Petros Fessas, Muntaha Naeem, Dominik Bettinger, Uqba Khan, Anwaar Saeed, Yi-Hsiang Huang, Masatoshi Kudo, Lorenza Rimassa, Thomas U. Marron, David J. Pinato, Celina Ang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors
Externí odkaz:
https://doaj.org/article/2cd3809960ca4aa790944f7a51d499a1
Autor:
Dominik Bettinger, David Szafron, Mahvish Muzaffar, Uqba Khan, Yi-Hsiang Huang, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Jingky Lozano-Kuehne, Celina Ang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
The impact of corticosteroid therapy (CT) on efficacy of immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS),
Externí odkaz:
https://doaj.org/article/fd5dfa2eba3b4f96a6696a68a05a1a49
Autor:
Gregory J. Riely, Natasha Rekhtman, Matthew D. Hellmann, Glenn Heller, Mark T.A. Donoghue, Barry S. Taylor, Charles M. Rudin, Tyler Jacks, Marc Ladanyi, Amanda Beras, Jennifer L. Sauter, Jason Chang, Yahya Daneshbod, Maria E. Arcila, Sonal Paul, Carla P. Concepcion, Jacklynn Egger, Hira Rizvi, Azadeh Namakydoust, Joseph Montecalvo, Jessica A. Lavery, Chai Bandlamudi, Adam J. Schoenfeld
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dda3733d557902a8a12ccb977083657
https://doi.org/10.1158/1078-0432.22479309
https://doi.org/10.1158/1078-0432.22479309
Autor:
Gregory J. Riely, Natasha Rekhtman, Matthew D. Hellmann, Glenn Heller, Mark T.A. Donoghue, Barry S. Taylor, Charles M. Rudin, Tyler Jacks, Marc Ladanyi, Amanda Beras, Jennifer L. Sauter, Jason Chang, Yahya Daneshbod, Maria E. Arcila, Sonal Paul, Carla P. Concepcion, Jacklynn Egger, Hira Rizvi, Azadeh Namakydoust, Joseph Montecalvo, Jessica A. Lavery, Chai Bandlamudi, Adam J. Schoenfeld
Overall survival by combination of STK11, KEAP1, and SMARCA4 alteration status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ec818030dc90fe8660d7d368364140
https://doi.org/10.1158/1078-0432.22479312
https://doi.org/10.1158/1078-0432.22479312
Autor:
Gregory J. Riely, Natasha Rekhtman, Matthew D. Hellmann, Glenn Heller, Mark T.A. Donoghue, Barry S. Taylor, Charles M. Rudin, Tyler Jacks, Marc Ladanyi, Amanda Beras, Jennifer L. Sauter, Jason Chang, Yahya Daneshbod, Maria E. Arcila, Sonal Paul, Carla P. Concepcion, Jacklynn Egger, Hira Rizvi, Azadeh Namakydoust, Joseph Montecalvo, Jessica A. Lavery, Chai Bandlamudi, Adam J. Schoenfeld
Purpose:SMARCA4 mutations are among the most common recurrent alterations in non–small cell lung cancer (NSCLC), but the relationship to other genomic abnormalities and clinical impact has not been established.Experimental Design:To characterize SM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6fa79eb27481fbd9afc8a67e3012aba
https://doi.org/10.1158/1078-0432.c.6530187
https://doi.org/10.1158/1078-0432.c.6530187
Autor:
Gregory J. Riely, Natasha Rekhtman, Matthew D. Hellmann, Glenn Heller, Mark T.A. Donoghue, Barry S. Taylor, Charles M. Rudin, Tyler Jacks, Marc Ladanyi, Amanda Beras, Jennifer L. Sauter, Jason Chang, Yahya Daneshbod, Maria E. Arcila, Sonal Paul, Carla P. Concepcion, Jacklynn Egger, Hira Rizvi, Azadeh Namakydoust, Joseph Montecalvo, Jessica A. Lavery, Chai Bandlamudi, Adam J. Schoenfeld
Frequency of altered individual genes within SMARCA4 Class 1 vs SMARCA4 Class 2 subgroups.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e926b8c5ea1c4082696b05c4906ffb2
https://doi.org/10.1158/1078-0432.22479306.v1
https://doi.org/10.1158/1078-0432.22479306.v1
Autor:
Hannah Hildebrand, Bo Yu, Sirish Dharmapuri, Neil Nimkar, Lorenz Balcar, Lorenza Rimassa, Pei-Chang Lee, Yehia I. Abugabal, Celina Ang, Tiziana Pressiani, David Szafron, Ahmed Kaseb, David J. Pinato, Anushi Bulumulle, Yinghong Wang, Uqba Khan, Sonal Paul, Naoshi Nishida, Mahvish Muzaffar, Muntaha Naeem, Anwaar Saeed, Yi Hsiang Huang, Thomas U. Marron, Tomi Jun, Matthias Pinter, Petros Fessas, Elad Sharon, Nicola Personeni, Musharraf Navaid, Dominik Bettinger, Anjana Pillai, Abdul Rafeh Naqash, Alessio Cortellini, Masatoshi Kudo, Anuhya Gampa
Publikováno v:
Liver Cancer, Vol 10, Iss 6, Pp 583-592 (2021)
Liver Cancer
Liver cancer, 10(6):583-592
Liver Cancer
Liver cancer, 10(6):583-592
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indicatio
Publikováno v:
Blood
Introduction: The outbreak of a novel infection, COVID-19, has greatly impacted the well-being of individuals worldwide. Persons with sickle cell disease (SCD) constitute a vulnerable population, subject to health disparities, who may have worse outc